Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Trial of Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of the Fully Human Monoclonal Antibody to RANKL (TK006) in Post-menopausal Women.

NCT03242512 is registered in ClinicalTrials.gov with Jiangsu T-Mab Biopharma Co.,Ltd as lead sponsor.

NCT NCT03242512
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03242512 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Trial of Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of the Fully Human Monoclonal Antibody to RANKL (TK006) in Post-menopausal Women.
Lead sponsor
Jiangsu T-Mab Biopharma Co.,Ltd
Phase
Phase 1
Overall status
Unknown status
Start date
August 7, 2017
Completion date
December 30, 2018
Enrollment
24 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

osteoporosis